tbuckley/cabot-search huggingface dataset:
Levels and trends in contraceptive prevalence, unmet need, and demand for family planning for 29 states and union territories in India: a modelling study using the Family Planning Estimation Tool
Authors: Jin Rou New, Niamh Cahill, John Stover, Yogender Pal Gupta, Leontine Alkema
Journal: The Lancet Global Health (2017)

Improving access to reproductive health services and commodities is central to development. Efforts to assess progress on this front have been largely focused on national estimates, but such analyses can mask local disparities. We assessed progress in reproductive health services subnationally in India.We developed a statistical model to generate estimates and projections of levels and trends in family planning indicators for subpopulations. The model builds onto the UN Population Division's Family Planning Estimation Model and uses data from multiple rounds of the Demographic and Health Survey, the District Level Household & Facility Survey, and the Annual Health Survey. We present annual estimates and projections of levels and trends in the prevalence of modern contraceptive use, and unmet need and demand for family planning for 29 states and union territories in India from 1990 to 2030. We also compared projections of demand satisfied with modern methods with the proposed goal of 75%.There is a large amount of heterogeneity in India, with a difference of up to 55·1 percentage points (95% uncertainty interval 46·4-62·1) in modern contraceptive use in 2015 between subregions. States such as Andhra Pradesh, with 92·7% (90·9-94·2) demand satisfied with modern methods, are performing well above the national average (71·8%, 56·7-83·6), whereas Manipur, with 26·8% (16·7-38·5) of demand satisfied, and Meghalaya, with 45·0% (40·1-50·0), consistently lag behind the rest of the country. Manipur and Meghalaya require the highest percentage increase in modern contraceptive use to achieve 75% demand satisfied with modern methods by 2030. In terms of absolute numbers, Uttar Pradesh requires the greatest increase, needing 9·2 million (5·5-12·6 million) additional users of modern contraception by 2030 to meet the target of 75%.The demand for family planning among the states and union territories in India is highly diverse. Greatest attention is needed in Uttar Pradesh, Manipur, and Meghalaya to meet UN targets. The analysis can be generalised to other countries as well as other subpopulations.Avenir Health through a grant from the Bill & Melinda Gates Foundation.
359O_PR Efficacy and safety of pembrolizumab (MK-3475) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Subset analyses for Asia-pacific patients in KEYNOTE-012 (KN-012) B2 cohort
Authors: M. Tahara, K. Muro, Y. Hasegawa, H.C. Chung, C-C. Lin, B. Keam, J. Cheng, Y-J. Bang
Journal: Annals of Oncology (2016)
A Phase II Clinical Trial of the Anti-EGFR Antibody Cetuximab in Patients with Refractory or Relapsed Multiple Myeloma: Final Results,
Authors: Bastian von Tresckow, Boris Böll, Dennis A. Eichenauer, Denissa Peine, Stefan Knop, Mariele Goebeler, Jens M. Chemnitz, Michael Hallek, Andreas Engert, Kai Hübel
Journal: Blood (2011)
Safety of zoledronic acid in patients who have previously received bisphosphonate therapy
Authors: R. Yanagihara, C. L. Vogel, A. J. Wood, F. M. Schnell, C. Henderson, B. H. Kaplan, M. H. Purdy, R. Orlowski, J. Decker, L. Lacerna
Journal: Journal of Clinical Oncology (2004)

8156 Background: Because pamidronate was the previous standard of care for patients with bone involvement from breast cancer, many patients will be treated with zoledronic acid after exposure to pamidronate. Therefore, it is important to demonstrate that switching patients from pamidronate to zoledronic acid will not result in an increase in bisphosphonate-related side effects. A phase IV study was conducted to examine the benefits of zoledronic acid on pain palliation and quality of life and to assess the overall and renal safety profile of zoledronic acid in patients with breast cancer, prostate cancer, and multiple myeloma with or without a history of bisphosphonate therapy. Methods: Zoledronic acid (4 mg) was administered via 15-minute infusion every 3 or 4 weeks for 6 infusions. Adverse events were recorded, and serum creatinine was measured before each infusion. Notable serum creatinine increases were defined as ≥ 0.5 mg/dL, if baseline was < 1.4 mg/dL; ≥ 1 mg/dL, if baseline was ≥ 1.4 mg/dL; or as any doubling of serum creatinine. Adverse events and serum creatinine levels were reported by tumor type and history of bisphosphonate therapy. Results: Among 638 patients, 415 (65%) had received prior bisphosphonate therapy, primarily pamidronate (95.4%). Among 461 patients with pain at baseline, mean pain scores decreased significantly (P < .01) at every postbaseline assessment. The most frequent adverse events in all patient groups were fatigue, nausea, and arthralgia. Notable serum creatinine increases occurred in 6.3% of patients and were somewhat more common in patients with a history of bisphosphonate therapy (7.7%) versus bisphosphonate-naive patients (4.5%). Treatment delays from serum creatinine increase occurred in 1.5% of patients with prior bisphosphonate exposure and 0.5% of bisphosphonate-naive patients. However, elevations in serum creatinine and treatment delays did not correlate with duration of prior bisphosphonate therapy or tumor type. Conclusions: Zoledronic acid (4 mg via 15-minute infusion) is safe and well tolerated in patients who have received prior bisphosphonate therapy, regardless of therapy duration. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Pharmaceuticals Corp. Novartis Pharmaceuticals Corp. Novartis Pharmaceuticals
Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen
Authors: Deborah A. Thomas, Hagop M. Kantarjian, Jeffrey L. Jorgensen, Stefan Faderl, Elias Jabbour, Marina Konopleva, Farhad Ravandi, Guillermo Garcia-Manero, Tapan M. Kadia, Gautam Borthakur, Jan A. Burger, Srdan Verstovsek, Alessandra Ferrajoli, William G. Wierda, Steven M. Kornblau, Michael Andreeff, Rebecca Garris, Sa A. Wang, Zeev Estrov, Jorge E. Cortes, Susan O'Brien
Journal: Blood (2012)
A systematic review of the incidence of venous thromboembolism (VTE) and effectiveness of prophylaxis in patients with multiple myeloma (MM) receiving thalidomide
Authors: C. M. Wu, A. Y. Lee
Journal: Journal of Clinical Oncology (2007)

9056 Background: Thalidomide (T) is effective for treating MM but is associated with an increased incidence of VTE, especially when combined with other agents. Consequently, prophylaxis in patients receiving T-containing regimens has been recommended. However, the true risk of VTE is uncertain and the effectiveness of prophylaxis has not been established. We performed a systematic review to determine the incidence of VTE and the effect of prophylaxis in MM patients receiving T-containing regimens. Methods: MEDLINE and EMBASE were searched from 1966 to 11/16/2006. Only randomized controlled trials (RCT) and prospective cohort studies (PC) were included. Studies evaluating post-transplant maintenance therapy were excluded. Both authors independently screened and reviewed identified publications, and extracted data of pre-specified variables. Incidence estimates were calculated as proportions along with 95% CI. Results: 363 papers were identified but only 80 were relevant and reviewed. 45 studies (6 RCT and 39 PC) involving 1,886 patients receiving T-containing regimens met inclusion criteria. 9 studies clearly stated objective testing was used to confirm a diagnosis of VTE. The incidence of VTE is summarized in the table . We found 12 trials that used prophylaxis. None included appropriate control groups to allow assessment of effectiveness. Based on limited data, the incidences of VTE with prophylaxis were: ASA 13.9% (95% CI 9.1–19.9%), fixed low- dose warfarin 21.9% (95% CI 16.9–27.5%), therapeutic-dose warfarin 0% (95% CI 0–5.5%), and low molecular weight heparin 13.3% (95% CI 10.5- 16.6%). Conclusions: The incidence of VTE in MM patients receiving T-containing regimens ranges from 3% to 22%, depending on the patient type and agents used. Given the lack of level I/II evidence, recommendation for routine prophylaxis for patients receiving T- containing regimens is premature. A safe and effective antithrombotic regimen has yet to be identified. [Table: see text] No significant financial relationships to disclose.
What Is the Cost-Effectiveness of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Monotherapy for the Treatment of Follicular Lymphoma Patients Who Relapse after or Are Refractory to a Rituximab-Containing Regimen in the US?
Authors: Gregory F. Guzauskas, Anthony Masaquel, Carolina Reyes, Kenneth Wilhelm, Tania Krivasi, David L. Veenstra
Journal: Blood (2016)
Comprehensive Assessment of Cytokines and Chemokines In Patients with Waldenstrom's Macroglobulinemia Reveals a Distinct Profile with Pathobiological and Clinical Relevance
Authors: Megan Lewicki, Bryan Ciccarelli, Zachary Hunter, Philip Brodsky, Robert Manning, Christina Hanzis, Christopher Patterson, Patricia Sheehy, Steven P. Treon
Journal: Blood (2010)
Suppressor of Cytokine Signaling-3 (SOCS3) Selectively Modulates Progenitor Cell Proliferation and Differentiation Induced by G-CSF and IL-6, and the Synergy between SCF and IL-6.
Authors: Andrew W. Roberts, Lisa Mielke, Sam Wormald, Hiu Kiu, Ben A. Croker, Douglas J. Hilton, Donald Metcalf, Warren S. Alexander
Journal: Blood (2006)
Changes in TNFR1 Levels in the First Week Post-Myeloablative HSCT Correlate with Severity and Incidence of GVHD and 1y TRM.
Authors: John E. Levine, Carrie Kitko, Gregory Yanik, Thomas Braun, Sophie Paczesny, Shin Mineishi, Oleg Krijanovski, Dawn Jones, Kenneth R. Cooke, Joel Whitfield, Raymond J. Hutchinson, James L.M. Ferrara
Journal: Blood (2006)
Abstract 12031: Initiation, Continuation, or Withdrawal of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction
Authors: Lauren G Gilstrap, Gregg C Fonawow, Liang Li, Adam DeVore, Eric E Smith, Paul Heidenreich, Adrian F Hernandez, Clyde W Yancy, Deepak L Bhatt
Journal: Circulation (2016)

Background: Guidelines recommend continuation or initiation of treatment with angiotensin converting enzyme inhibitors/angiotensin II receptor blockers (ACEi/ARB) in hospitalized patients with heart failure with reduced ejection fraction (HFrEF). Methods: Using data from Get With The Guidelines-Heart Failure, we linked 16,052 HFrEF patients with Medicare claims. We divided patients into 4 categories based on admission and discharge ACEi/ARB use: continued, started, discontinued, or not started. A multivariable Cox proportional hazard model was performed to determine the association between the categories and 30-day, 90-day and 1-year outcomes. Results: A total of 90.6% of patients were discharged on ACEi/ARB (59.6% continued, 30.9% started, 1.9% discontinued, 7.5% not started). The 30-day mortality rate was higher, 8.8% for those discontinued (HR adj 2.04; 95% CI 1.42, 2.92; P&lt;0.001) and 7.5% for those not started (HR adj 1.55; 95% CI 1.16, 2.07, P=0.003), compared with 3.5% for those continued on ACEi/ARB. There was no significant difference in 30-day mortality between those continued and those started. The 30-day readmission rate was higher, 28.6% for those discontinued (HR adj 1.44; 95% CI 1.19, 1.75; P&lt;0.001) and 23.3% for those not started (HR adj 1.17, 95% CI 1.03, 1.32, P=0.013), compared with 18.3% for those continued on ACEi/ARB. Again, there was no significant difference in 30-day readmissions between those continued and those started. By one year, the mortality rate was lowest among those continued on ACEi/ARB compared to those discontinued (HR adj 1.42; 95% CI 1.18, 1.70, P&lt;0.001) or not started (HR adj 1.32, 95% CI 1.18, 1.47, P&lt;0.001). Conclusions: Initiation or continuation of ACEi/ARB therapy after an admission with HFrEF is associated with lower 30-day mortality and readmission rates. The lower mortality associated with continuing ACEi/ARB therapy persists out to 1 year.
Quantitation of follicular non-Hodgkin's lymphoma cells carrying t(14; 18) in a patient before and after allogeneic bone marrow transplantation
Authors: J.P.P. Meijerink, G.J. Goverde, T.F.C.M. Smetsers, J.M.M. Raemaekers, M.J.J.T. Bogman, T. de Witte, E.J.B.M. Mensink
Journal: Annals of Oncology (1994)
Benefits and safety of multigene panel testing in patients at risk for hereditary breast cancer.
Authors: Nimmi S. Kapoor, Lisa D. Curcio, Carlee A. Blakemore, Amy K. Bremner, Rachel E. McFarland, John G. West, Kimberly C. Banks
Journal: Journal of Clinical Oncology (2015)

16 Background: Recently introduced multi-gene panel testing including BRCA1 and BRCA2 genes (BRCA1/2) for hereditary cancer risk has raised concerns with the ability to detect all deleterious BRCA1/2 mutations compared to older methods of sequentially testing BRCA1/2 separately. The purpose of this study is to evaluate rates of pathogenic BRCA1/2mutations and variants of uncertain significance (VUS) between previous restricted algorithms of genetic testing and newer approaches of multi-gene testing. Methods: Data was collected retrospectively from 966 patients who underwent genetic testing at one of three sites from a single institution. Test results were compared between patients who underwent BRCA1/2testing only (limited group, n = 629) to those who underwent multi-gene testing with 5-43 cancer-related genes (panel group, n = 337). Results: Deleterious BRCA1/2 mutations were identified in 37 patients, with equivalent rates between limited and panel groups (4.0% vs 3.6%, respectively, p = 0.86). Thirty-nine patients had a BRCA1/2 VUS, with similar rates between limited and panel groups (4.5% vs 3.3%, respectively, p = 0.49). On multivariate analysis, there was no difference in detection of either BRCA1/2 mutations or VUS between both groups. Of patients undergoing panel testing, an additional 3.9% (n = 13) had non-BRCA pathogenic mutations and 13.4% (n = 45) had non-BRCA VUSs. Mutations in PALB2, CHEK2, and ATM were the most common non-BRCA mutations identified. Conclusions: Multi-gene panel testing detects pathogenic BRCA1/2 mutations at equivalent rates as limited testing and increases the diagnostic yield. Panel testing increases the VUS rate, mainly due to non-BRCA genes. Patients at risk for hereditary breast cancer can safely benefit from upfront, more efficient, multi-gene panel testing.
Statistical Concerns on Vismodegib for Basal Cell Carcinoma Meta-Analysis—Reply
Authors: Audrey A. Jacobsen, John Strasswimmer
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
33P Somatic mutations of PIK3CA and AKT1 in Japanese breast cancer
Authors: T. Shimoi, A. Hamada, Y. Kitamura, T. Nishijo, A. Shimomura, C. Shimizu, M. Yoshida, T. Kinoshita, Y. Fujiwara, K. Tamura
Journal: Annals of Oncology (2016)
NIMG-18. IMPACT OF THE VOLUMES OF DIFFERENT TUMOR COMPONENTS IN GLIOBLASTOMA ON OVERALL SURVIVAL
Authors: Severina Leu, Jean-Louis Boulay, Sarah Thommen, Heiner Bucher, Christoph Stippich, Luigi Mariani, Andrea Bink
Journal: Neuro-Oncology (2016)

To determine the impact of different tumor components in glioblastoma (GBM) on the overall survival (OS). Retrospective analysis of 64 GBM patients operated between 2009 and 2014 was performed. Demographic data was extracted from our tumor database and volumetric data from the preoperative magnetic resonance images (MRI) using the visual Automated Brainstem Co-registration (ABC)-method. For each patient, four different volumes in ml were assessed: enhancing, non-enhancing, necrosis and edema. In addition, preoperative Response Assessment in Neuro-Oncology (RANO) in mm2 and postoperative enhancing residual volume in ml was measured. Multivariable cox proportional hazard models were used to associate the different tumor components with OS adjusting for the potential confounders age and postoperative enhancing residual tumor. We analyzed the data of 64 patients with a median age of 63 years (interquartile range (IQR) 56-70). The majority of the patients had a total (37), 17 a subtotal tumor resection and 10 a biopsy only. Median preoperative enhancing tumor volume was 18.2 ml and median remnant tumor volume was 1%. During follow up 59 patients (92%) died; both median survival time and median follow up time were 404 days. Preliminary results show significant multiplicative effect of RANO on the hazard for death; Hazard ratio (HR) increases of 1.071 per unit increase of 200 mm2 (95%-CI 1.004-1.143; p-value 0.04). Furthermore, age at surgery and log transformed remnant tumor were ­estimated to have a statistically significant increasing effect on HR (1.071 per year of age increase (95%-CI 1.032-1.111; p-value < 0.01), and 1.113 per unit increase of log2transformed remnant tumor in percent (95%-CI 1.046-1.185; p-value < 0.01)). There is no evidence in our data for an effect of any other investigated tumor component on OS. The presented data suggests that preoperative RANO measurement has a prognostic effect in GBM patients.
Prognostic value of the immune-related transcriptome in biliary tract cancers
Authors: M. Ghidini, L. Cascione, A. Lampis, R. Pandolfo, P. Carotenuto, F. Trevisani, J.C. Hahne, D. Zito, V. Guzzardo, A. Zerbi, G. Torzilli, M. Roncalli, L. Rimassa, A. Santoro, M. Fassan, N. Valeri, C. Braconi
Journal: Annals of Oncology (2016)
Karyotype Plus NPM1 Mutation Status Defines a Group of Elderly Patients with AML (≥60 Years) Who Benefit From Intensive Post-Induction Consolidation Therapy
Authors: Wolfgang R. Sperr, Otto Zach, Iris Poell, Michael Kundi, Susanne Herndlhofer, Ulrich Jaeger, Paul Knoebl, Ansgar Weltermann, Peter Valent
Journal: Blood (2011)
Retinal and Optic Nerve Degeneration in Patients with Multiple Sclerosis Followed up for 5 Years
Authors: Elena Garcia-Martin, Jose R. Ara, Jesus Martin, Carmen Almarcegui, Isabel Dolz, Elisa Vilades, Laura Gil-Arribas, Francisco J. Fernandez, Vicente Polo, Jose M. Larrosa, Luis E. Pablo, Maria Satue
Journal: Ophthalmology (2017)
A pilot phase II study with brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma: A preliminary report.
Authors: Massimo Federico, Emanuela Anna Pesce, Francesco Merli, Stefano Luminari, Stephane Chauvie, Cinzia Pellegrini, Luigi Marcheselli, Isabella Capodanno, Fiorella Ilariucci, Massimiliano Salati, Lisa Argnani, Pier Luigi Zinzani
Journal: Journal of Clinical Oncology (2014)

8507 Background: In the majority of patients with relapsed or refractory Hodgkin Lymphoma (HL) Brentuximab vedotin (BV) has shown significant activity, with a manageable safety profile. We aimed to assess the role of 2 cycles of BV before starting the standard treatment with ABVD +/- RT in patients with previously untreated HL. Methods: Patients with previously untreated CD30-positive HL, stage IA or IIA or IIIA, absence of bulky disease, defined as a mediastinal mass greater than one-third of the maximum chest diameter, or any other mass greater than or equal to 10 cm, received 2 cycles of BV 1.8 mg/Kg intravenously every 3 weeks over 30 minutes, as an outpatient infusion, followed by 3-6 cycles of ABVD depending on stage. Decision on radiotherapy was at physician’s discretion. The primary endpoint of the study was the response to BV assessed by FDG/PET, defined as reduction of Deauville score or, in case of no change in Deauville score, as any reduction in SUV intensity compared to basal SUV. PET results (baseline and after 2 cycles of BV) were assessed by a panel of three external independent reviewers. The sample size was fixed at 12 patients. The treatment was considered promising if 10 or more responses were observed (response rate 83%, 95%CI 52-98%). Results: Between April and October 2013, 12 patients with a median age of 36 years (age range: 19-70 years), eleven in stage II (Early favorable 7, early unfavorable 4, according to EORTC criteria) and one in stage III, were enrolled. BV was administered as scheduled and at the full dose in all patients. After the 2 cycles of BV, all patients but one (91%) responded, ten with complete (83%) and one (8%) with partial metabolic response. Of note, all seven patients with early favorable disease achieved a complete metabolic response. The only non responding patient had stage III and showed a new lesion at PET2. The only grade 3 adverse events were transient and asymptomatic increase in liver transaminases (n=3, 25%) and gamma glutamyl transpeptidase (n=2, 17%). Conclusions: Two cycles of BV induced a complete metabolic response in the majority of patients with previously untreated, limited stage HL, and warrant further studies in first line therapy.